Equity Profile

IDYA

IDEAYA Biosciences, Inc.

Health CareBiotechnology$3.5B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

IDEAYA Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability, and investors will be keen to see if the company can narrow its losses this quarter.

$-1.07

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would indicate progress in their product development and market acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IDYA Q2-2026 Earnings Preview

Context

Company Snapshot

IDEAYA Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for cancer. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as advancements in personalized medicine continue to evolve.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+8281.73%

Avg Stock Reaction

-2.69%

Last Quarter Recap

In Q1-2026, IDEAYA reported an EPS of -$1.11, slightly missing expectations. The stock reacted negatively, dropping 0.35% the following day.

Management Promises & Guidance

Continue advancing clinical trials for their cancer therapies.
Focus on strategic partnerships to enhance development capabilities.
Commit to improving operational efficiency to reduce costs.

Expectations

Wall Street Expectations

Overall, expectations are cautious as the company has a mixed earnings history, with recent quarters showing both beats and misses.

Bull Case

If IDEAYA can show significant progress in its clinical trials and narrow its EPS loss, it could signal strong future growth potential, attracting more investors.

Bear Case

Conversely, if the company fails to meet expectations again, it may raise concerns about its long-term viability and lead to further stock declines.

Key Metrics to Watch

Earnings Per Share (EPS)

$-1.07

EPS is a key indicator of profitability, and investors will be keen to see if the company can narrow its losses this quarter.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue would indicate progress in their product development and market acceptance.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS for Q2-2026 be better than the expected -$1.07?

A narrower loss could indicate improved operational efficiency and investor confidence.

What updates can management provide on the progress of their clinical trials?

Investors will be looking for any signs of success or setbacks that could impact future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of IDEAYA's clinical trial advancements, which could lead to a faster path to revenue than anticipated.

Supporting Evidence

The company has a history of surprising the market with unexpected trial results.

Options pricing suggests a significant move, indicating that traders believe there is more volatility ahead.

The recent trend of EPS surprises shows that the company has the potential to exceed expectations.

Key Risk

If the clinical trial updates are more positive than expected, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for recovery against the backdrop of previous misses and the company's ongoing clinical development.

Bull Confirmed If

An EPS loss of less than -$1.07 with positive updates on clinical trials would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$1.07 and negative updates on clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±13.3%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±13.3% while IDYA has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

36.9%

Calls (2K)P/C Ratio: 0.10Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If IDEAYA beats EPS expectations and provides positive trial updates, history suggests the stock could rise by about 1.2%.

In-Line / Cautious

If the results are in line with expectations but lack strong commentary, the stock may react neutrally, reflecting uncertainty.

Miss

If the company misses expectations again, history suggests a potential decline of around 5%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific updates on the status of ongoing clinical trials.
2Management's commentary on cost management and operational efficiency.
3Insights into potential partnerships or collaborations.
4Future guidance on revenue expectations and product pipeline.
5Responses to analyst questions regarding competitive positioning.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

IDEAYA Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability, and investors will be keen to see if the company can narrow its losses this quarter.

$-1.07

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would indicate progress in their product development and market acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IDYA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+8281.73%

Avg Stock Reaction

-2.69%

Last Quarter Recap

In Q1-2026, IDEAYA reported an EPS of -$1.11, slightly missing expectations. The stock reacted negatively, dropping 0.35% the following day.

Management Promises & Guidance

Continue advancing clinical trials for their cancer therapies.
Focus on strategic partnerships to enhance development capabilities.
Commit to improving operational efficiency to reduce costs.

Expectations

Wall Street Expectations

Overall, expectations are cautious as the company has a mixed earnings history, with recent quarters showing both beats and misses.

Bull Case

If IDEAYA can show significant progress in its clinical trials and narrow its EPS loss, it could signal strong future growth potential, attracting more investors.

Bear Case

Conversely, if the company fails to meet expectations again, it may raise concerns about its long-term viability and lead to further stock declines.

Key Metrics to Watch

Earnings Per Share (EPS)

$-1.07

EPS is a key indicator of profitability, and investors will be keen to see if the company can narrow its losses this quarter.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue would indicate progress in their product development and market acceptance.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS for Q2-2026 be better than the expected -$1.07?

A narrower loss could indicate improved operational efficiency and investor confidence.

What updates can management provide on the progress of their clinical trials?

Investors will be looking for any signs of success or setbacks that could impact future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of IDEAYA's clinical trial advancements, which could lead to a faster path to revenue than anticipated.

Supporting Evidence

The company has a history of surprising the market with unexpected trial results.

Options pricing suggests a significant move, indicating that traders believe there is more volatility ahead.

The recent trend of EPS surprises shows that the company has the potential to exceed expectations.

Key Risk

If the clinical trial updates are more positive than expected, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for recovery against the backdrop of previous misses and the company's ongoing clinical development.

Bull Confirmed If

An EPS loss of less than -$1.07 with positive updates on clinical trials would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$1.07 and negative updates on clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±13.3%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±13.3% while IDYA has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

36.9%

Calls (2K)P/C Ratio: 0.10Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If IDEAYA beats EPS expectations and provides positive trial updates, history suggests the stock could rise by about 1.2%.

In-Line / Cautious

If the results are in line with expectations but lack strong commentary, the stock may react neutrally, reflecting uncertainty.

Miss

If the company misses expectations again, history suggests a potential decline of around 5%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific updates on the status of ongoing clinical trials.
2Management's commentary on cost management and operational efficiency.
3Insights into potential partnerships or collaborations.
4Future guidance on revenue expectations and product pipeline.
5Responses to analyst questions regarding competitive positioning.